Back to Awarded Treatment Trials
Awarded Trial: 02T-264
Grant ID
02T-264
Illness
Schizophrenia
Primary Drug/Intervention
Flunarizine
Primary Dosage
10mg-50mg
Secondary Drug Intervention
Haloperidol
Secondary Dosage
2.5mg-12.5mg
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Lara
Sample Size
70
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
PANSS, ESRS, Cognitive Battery
Results
Flunarizine is a mild D2 Antagonist and T-type calcium channel blocker. Patients randomized to receive flunarizine had a reduction in psychiatric symptom ratings that was comparable to haloperidol. There was a slight advantage for the flunarizine treated group on one cognitive test (digit-span). Flunarizine treated patients had some extrapyramidal side effects, prolactin elevation and weight gain.
Publication
N/A
Link
N/A
PI Name
Diogo Lara
Degree
MD
Center
PUCRS, Faculdade de Biociencias, Dept. of Psychiatry
Institution
Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS)
Address
Av. Ipiranga, 6681, Pd 12A
City or Town
Porto Alegre
State or Province
RS
Zip or Postal Code
90619
Country
Brazil
Email Address
drlara@pucrs.br